Get the Stockscreener App
0.8221
6.49%
0.0501
Pre-market:
.82
-0.0021
-0.26%
Briacell Therapeutics Corp stock is traded at $0.8221, with a volume of 3.02M.
It is up +6.49% in the last 24 hours and down -73.98% over the past month.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
See More
Previous Close:
$0.772
Open:
$0.8024
24h Volume:
3.02M
Relative Volume:
1.48
Market Cap:
$5.39M
Revenue:
-
Net Income/Loss:
$-16.60M
P/E Ratio:
-0.9237
EPS:
-0.89
Net Cash Flow:
$-23.48M
1W Performance:
-61.04%
1M Performance:
-73.98%
6M Performance:
-85.76%
1Y Performance:
-94.40%
1-Day Range:
$0.8024
$0.8422
1-Week Range:
$0.69
$2.1798
52-Week Range:
$0.69
$29.40
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Name
Briacell Therapeutics Corp
Sector
Industry
Phone
(604) 921-1810
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Compare BCTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
0.8221 | 14.30M | 0 | -16.60M | -23.48M | -0.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.55 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.93 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.81 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.92 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
279.16 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-22 | Initiated | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Stock (BCTX) Latest News
BriaCell Therapeutics Secures $15 Million in Public Offering - TipRanks
BriaCell Therapeutics Announces Closing of $15 million Public Offering - GlobeNewswire
BriaCell Secures $15M Funding Boost for Cancer Immunotherapy Development at $1.25 Per Unit - Stock Titan
BCTX files $15M unit offering; share count could triple post-deal | CMCL SEC FilingForm 6-K - Stock Titan
BriaCell Prices $15 Mln Public Offering To Fund Operations And Growth Initiatives - Nasdaq
BriaCell Therapeutics (BCTX) Plunges 61.78% After $15M Public Offering - AInvest
BriaCell (BCTX) Announces $15M Public Offering of Common Shares and Warrants | BCTX Stock News - GuruFocus
BriaCell Therapeutics Announces Pricing of $15 million Public Offering | BCTX Stock News - GuruFocus
BriaCell says $15M unit offering prices at $1.25 per unit - TipRanks
Briacell Therapeutics announces pricing of $15 million public offering - MarketScreener
BriaCell Therapeutics Announces Pricing of $15 million Public Offering - GlobeNewswire
Cancer Immunotherapy Developer BriaCell Secures $15M Funding: What the Deal Means for Investors - Stock Titan
BCTX Stock Surges Amid Positive Developments and Strategic Moves - StocksToTrade
(BCT) Proactive Strategies (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics Adds Mayo Clinic to Late-Stage Study in Metastatic Breast Cancer - MarketScreener
BriaCell adds Mayo Clinic to Phase 3 study in metastatic breast cancer - TipRanks
BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer - GlobeNewswire
Mayo Clinic Partners with BriaCell for Groundbreaking Phase 3 Breast Cancer Immunotherapy Study - Stock Titan
When the Price of (BCT) Talks, People Listen (BCT:CA) - news.stocktradersdaily.com
BriaCell Shares Slide 22% After Announcing Dilutive Public Offering - MSN
Briacell stock maintains Buy rating at H.C. Wainwright on strong survival data - Investing.com Australia
BriaCell Therapeutics Corp. - Baystreet.ca
BriaCell announces updated Phase 2 survival data fro Bria-IMT - TipRanks
BriaCell’s Bria-IMT Shows Promising Survival Advantage in Metastatic Breast Cancer - TipRanks
BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer - GlobeNewswire
Clinical Trial: New Breast Cancer Drug Shows 17.3-Month Survival Rate, Beating Current Standard of Care - Stock Titan
BriaCell Achieves Milestone in Metastatic Breast Cancer Study with Bria-OTS - TipRanks
Promising Clinical Developments and Positive Outlook Justify Buy Rating for BriaCell Therapeutics - TipRanks
BriaCell’s Bria-IMT Shows Promising Results in Advanced Breast Cancer Treatment - TipRanks
BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient - Santé log
BriaCell Reports Complete and Sustained Resolution of Brain - GlobeNewswire
Breakthrough: Complete Brain Tumor Resolution in Patient Who Failed 8 Prior Cancer Treatments - Stock Titan
BriaCell Therapeutics Corp (BCTX) Plunges 29.55% Amid Public Offering Concerns - AInvest
BriaCell Therapeutics stock tumbles after announcing public offering By Investing.com - Investing.com South Africa
BriaCell Therapeutics stock tumbles after announcing public offering - Investing.com
BriaCell Plunges 23.33% Amid IPO Registration Amendments - AInvest
BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study - Santé log
BriaCell Patient Achieves Sustained Complete Resolution of - GlobeNewswire
Breakthrough: BriaCell's Cancer Therapy Eliminates Lung Metastasis in Advanced Breast Cancer Patient - Stock Titan
BriaCell reports 52% one-year survival rate in metastatic breast cancer trial By Investing.com - Investing.com South Africa
Form FWP BriaCell Therapeutics Filed by: BriaCell Therapeutics Corp. - StreetInsider
BriaCell’s Phase 2 Study Shows Promising Survival Rates in Metastatic Breast Cancer - TipRanks
BriaCell reports 52% one-year survival rate in metastatic breast cancer trial - Investing.com
BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer - GlobeNewswire
Breakthrough: New Cancer Drug Shows 52% Survival Rate Where Standard Treatments Failed - Stock Titan
BriaCell Expands Phase 3 Cancer Study with New Clinical Sites - TipRanks
BriaCell Highlights Additional Phase 3 Clinical Sites - GlobeNewswire
BriaCell adds two major cancer centers to Phase 3 breast cancer study - Investing.com
BriaCell’s Phase 3 Study in Metastatic Breast Cancer Receives Positive DSMB Recommendation - TipRanks
BriaCell Therapeutics: Stocks Undervalued by Analyst Consensus on TSX (BCT) - The Globe and Mail
BriaCell Reports Increased Losses in Latest Financials - TipRanks
Briacell Therapeutics Corp Stock (BCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.40%
2.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):